HOLX launches Ultimate Defense, a new U.S. campaign that urges routine Pap + HPV screening to boost awareness and help curb ...

The global automated nucleic acid extraction market size was valued at US$ 3.6 Bn in 2025 and is projected to reach US$ 11.7 ...

In my short stint as a resident doctor in oncology, the overwhelming impression was one of complex and expensive treatments doing little for patient survival or quality of life. The options available ...

Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for myotonic dystrophy type 1 (DM1), the most common adult-onset form of ...

An LMU research team led by Professor Olivia M. Merkel, Chair of Drug Delivery at LMU, has developed a new delivery system ...

The head of the Department of Health and Human Services has spent decades promoting vaccine skepticism and has now revamped the US childhood immunization schedule to have one-third fewer recommended ...

ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...

The Commerce Department is floating a proposal that would impede the commercialization of university researchers’ most ...

The United States reported a record number of measles cases in 2025, and the virus continues to spread rapidly in the new year. At least ​171 measles cases have been reported in the first two weeks of ...

BK and CaV1.3 channels interact early during biogenesis, assembling intracellularly before membrane localization, indicating coordinated processes for functional coupling.

Benefits seen from embracing platform technologies, combined with the role such systems played during the pandemic, are key dynamics.

Jefferies analysts forecast a $1 billion market opportunity for each of Sarepta’s siRNA programs for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.